Skip to main content
Top
Published in: Diabetology International 4/2020

01-10-2020 | Type 1 Diabetes | Mini-Review

Genetics of fulminant type 1 diabetes

Authors: Yumiko Kawabata, Hiroshi Ikegami

Published in: Diabetology International | Issue 4/2020

Login to get access

Abstract

Since fulminant type 1 diabetes was reported as a distinct subtype of type 1 diabetes in 2000, the Committee on Type 1 diabetes, Japan Diabetes Society has continuously recruited patients and conducted genomic research to elucidate the genetic basis of fulminant type 1 diabetes. The contribution of the human leukocyte antigen complex (HLA) to genetic susceptibility to fulminant type 1 diabetes was compared with that of other subtypes in 2009. The alleles and haplotypes associated with fulminant type 1 diabetes were found to be different from acute-onset and slowly progressive type 1 diabetes. DRB1*15:01-DQB1*06:02, a protective haplotype against acute-onset type 1 diabetes, does not provide protection against fulminant type 1 diabetes and DRB1*08:02-DQB1*03:02, a susceptible haplotype to acute-onset type 1 diabetes, does not confer susceptibility to fulminant type 1 diabetes. Recently, the first genome-wide association study (GWAS) of fulminant type 1 diabetes was performed in Japanese individuals. A strong association was observed with multiple single nucleotide polymorphisms (SNPs) in the HLA region, and the strongest association was observed with rs9268853 in the class II DR region. In addition, 11 SNPs outside the HLA region showed some evidence of association with the disease. In particular, rs11170445 in CSAD/lnc-ITGB7-1 on chromosome 12q13.13 showed an association at a genome-wide significance level. Fine mapping revealed that rs3782151 in CSAD/lnc-ITGB7-1 showed the lowest P value. CSAD/lnc-ITGB7-1 was found to be strongly associated with susceptibility to fulminant, but not classical, autoimmune type 1 diabetes, implicating this locus in the distinct phenotype of fulminant type 1 diabetes.
Literature
1.
go back to reference Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes related antibodies. Osaka IDDM study group. N Engl J Med. 2000;342(5):301–7.PubMed Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes related antibodies. Osaka IDDM study group. N Engl J Med. 2000;342(5):301–7.PubMed
2.
go back to reference Imagawa A, Hanafusa T. Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners. Nat Clin Prac Endocrinol Metab. 2007;3:36–45. Imagawa A, Hanafusa T. Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners. Nat Clin Prac Endocrinol Metab. 2007;3:36–45.
3.
go back to reference Gianani R, Eisenbarth GS. The stages of type 1A diabetes: 2005. Immunol Rev. 2005;204:232–49.PubMed Gianani R, Eisenbarth GS. The stages of type 1A diabetes: 2005. Immunol Rev. 2005;204:232–49.PubMed
4.
go back to reference Bakay M, Pandey R, Grant SFA, Hakonarson H. The genetic contribution to type 1 diabetes. Curr Diab Rep. 2019;19:116.PubMed Bakay M, Pandey R, Grant SFA, Hakonarson H. The genetic contribution to type 1 diabetes. Curr Diab Rep. 2019;19:116.PubMed
5.
go back to reference Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J. Incidence of childhood type 1 diabetes worldwide. Diabetes mondiale (DiaMond) project group. Diabetes Care. 2000;23:1516–26.PubMed Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J. Incidence of childhood type 1 diabetes worldwide. Diabetes mondiale (DiaMond) project group. Diabetes Care. 2000;23:1516–26.PubMed
6.
go back to reference Ikegami H, Awata T, Kawasaki E, Kobayashi T, Maruyama T, Nakanishi K, Shimada A, Amemiya S, Kawabata Y, Kurihara S, Tanaka S, Kanazawa Y, Mochizuki M, Ogihara T. Japanese study group on type 1 diabetes genetics: the association of CTLA4 polymorphism with type 1 diabetes is concentrated in patients complicated with autoimmune thyroid disease: a multi-center collaborative study in Japan. J Clin Endocrinol Metab. 2006;91:1087–92.PubMed Ikegami H, Awata T, Kawasaki E, Kobayashi T, Maruyama T, Nakanishi K, Shimada A, Amemiya S, Kawabata Y, Kurihara S, Tanaka S, Kanazawa Y, Mochizuki M, Ogihara T. Japanese study group on type 1 diabetes genetics: the association of CTLA4 polymorphism with type 1 diabetes is concentrated in patients complicated with autoimmune thyroid disease: a multi-center collaborative study in Japan. J Clin Endocrinol Metab. 2006;91:1087–92.PubMed
7.
go back to reference Ikegami H, Kawabata Y, Noso S, Fujisawa T, Ogihara T. Genetics of type 1 diabetes in Asian and Caucasian populations. Diabetes Res Clin Pract. 2007;77(Suppl. 1):S116–S12121.PubMed Ikegami H, Kawabata Y, Noso S, Fujisawa T, Ogihara T. Genetics of type 1 diabetes in Asian and Caucasian populations. Diabetes Res Clin Pract. 2007;77(Suppl. 1):S116–S12121.PubMed
8.
go back to reference Cho YM, Kim JT, Ko KS, Koo BK, Yang SW, Park MH, Lee HK, Park KS. Fulminant type 1 diabetes in Korea: high prevalence among patients with adult-onset type 1 diabetes. Diabetologia. 2007;50:2276–9.PubMed Cho YM, Kim JT, Ko KS, Koo BK, Yang SW, Park MH, Lee HK, Park KS. Fulminant type 1 diabetes in Korea: high prevalence among patients with adult-onset type 1 diabetes. Diabetologia. 2007;50:2276–9.PubMed
9.
go back to reference Moreau C, Drui D, Arnault-Ouary G, Charbonnel B, Chaillous L, Cariou B. Fulminant type 1 diabetes in Caucasians: a report of three cases. Diabetes Metab. 2008;34:529–32.PubMed Moreau C, Drui D, Arnault-Ouary G, Charbonnel B, Chaillous L, Cariou B. Fulminant type 1 diabetes in Caucasians: a report of three cases. Diabetes Metab. 2008;34:529–32.PubMed
10.
go back to reference Rish N. Assessing the role of HLA-linked and unlinked determinants of disease. Am J Hum Genet. 1987;40:1–14. Rish N. Assessing the role of HLA-linked and unlinked determinants of disease. Am J Hum Genet. 1987;40:1–14.
11.
go back to reference Ikegami H, Oihara T. Genetics of insulin-dependent diabetes mellitus. Endocrine J. 1996;43:605–13. Ikegami H, Oihara T. Genetics of insulin-dependent diabetes mellitus. Endocrine J. 1996;43:605–13.
12.
go back to reference Noble JA, Valdes AM, Cook M, Klitz W, Thomson G, Erlich HA. The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families. Am J Hum Genet. 1996;59:1134–48.PubMedPubMedCentral Noble JA, Valdes AM, Cook M, Klitz W, Thomson G, Erlich HA. The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families. Am J Hum Genet. 1996;59:1134–48.PubMedPubMedCentral
13.
go back to reference Lambert AP, Gillespie KM, Thomson G, Cordell HJ, Todd JA, Gale EA, Bingley PJ. Absolute risk of childhood-onset type 1 diabetes defined by human leukocyte antigen class II genotype: a population-based study in the United Kingdom. J Clin Endocrinol Metab. 2004;89:4037–43.PubMed Lambert AP, Gillespie KM, Thomson G, Cordell HJ, Todd JA, Gale EA, Bingley PJ. Absolute risk of childhood-onset type 1 diabetes defined by human leukocyte antigen class II genotype: a population-based study in the United Kingdom. J Clin Endocrinol Metab. 2004;89:4037–43.PubMed
14.
go back to reference Todd J, Bell JI, MacDevitt HO. HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature. 1987;329:599–604.PubMed Todd J, Bell JI, MacDevitt HO. HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature. 1987;329:599–604.PubMed
15.
go back to reference Ikegami H, Kawaguchi Y, Yamato E, Kuwata S, Tokunaga K, Noma Y, Shima K, Ogiharaet T. Analysis by the polymerase chain reaction of histocompatibility leukocyte antigen-DR9-linked susceptibility to insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1992;75:1381–5.PubMed Ikegami H, Kawaguchi Y, Yamato E, Kuwata S, Tokunaga K, Noma Y, Shima K, Ogiharaet T. Analysis by the polymerase chain reaction of histocompatibility leukocyte antigen-DR9-linked susceptibility to insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1992;75:1381–5.PubMed
16.
go back to reference Kawabata Y, Ikegami H, Kawaguchi Y, Fujisawa T, Shintani M, Ono M, Nishino M, Uchigata Y, Lee I, Ogihara T. Asian-specific HLA haplotypes reveal heterogeneity of the contribution of HLA-DR and -DQ haplotypes to susceptibility to type 1 diabetes. Diabetes. 2002;51:545–51.PubMed Kawabata Y, Ikegami H, Kawaguchi Y, Fujisawa T, Shintani M, Ono M, Nishino M, Uchigata Y, Lee I, Ogihara T. Asian-specific HLA haplotypes reveal heterogeneity of the contribution of HLA-DR and -DQ haplotypes to susceptibility to type 1 diabetes. Diabetes. 2002;51:545–51.PubMed
17.
go back to reference Thomson G, Valdes AM, Noble JA, et al. Relative predispositional effects of HLA class II DRB1-DQB1 haplotypes and genotypes on type 1 diabetes: a meta-analysis. Tissue Antigens. 2007;70:110–27.PubMed Thomson G, Valdes AM, Noble JA, et al. Relative predispositional effects of HLA class II DRB1-DQB1 haplotypes and genotypes on type 1 diabetes: a meta-analysis. Tissue Antigens. 2007;70:110–27.PubMed
18.
go back to reference Ikegami H, Noso S, Babaya N, Hiromine Y, Kawabata Y. Genetic basis of type 1 diabetes: similarities and differences between East and West. Rev Diabet Stud. 2008;5:64–72.PubMedPubMedCentral Ikegami H, Noso S, Babaya N, Hiromine Y, Kawabata Y. Genetic basis of type 1 diabetes: similarities and differences between East and West. Rev Diabet Stud. 2008;5:64–72.PubMedPubMedCentral
19.
go back to reference Kawabata Y, Ikegami H, Awata T, Imagawa A, Maruyama T, Kawasaki E, Tanaka S, Shimada A, Osawa H, Kobayashi T, Hanafusa T, Tokunaga K, Makino H. Committee on type 1 diabetes, Japan diabetes society. Diabetologia. 2009;52:2513–21.PubMed Kawabata Y, Ikegami H, Awata T, Imagawa A, Maruyama T, Kawasaki E, Tanaka S, Shimada A, Osawa H, Kobayashi T, Hanafusa T, Tokunaga K, Makino H. Committee on type 1 diabetes, Japan diabetes society. Diabetologia. 2009;52:2513–21.PubMed
20.
go back to reference Tsutsumi C, Imagawa A, Ikegami H, Makino H, Kobayashi T, Hanafusa T. Japan diabetes society committee on type 1 diabetes mellitus research. Class II HLA genotype in fulminant type 1 diabetes: a nationwide survey with reference to glutamic acid decarboxylase antibodies. J Diabetes Investig. 2012;3:62–9.PubMed Tsutsumi C, Imagawa A, Ikegami H, Makino H, Kobayashi T, Hanafusa T. Japan diabetes society committee on type 1 diabetes mellitus research. Class II HLA genotype in fulminant type 1 diabetes: a nationwide survey with reference to glutamic acid decarboxylase antibodies. J Diabetes Investig. 2012;3:62–9.PubMed
21.
go back to reference Imagawa A, Hanafusa T. Fulminant type 1 diabetes–an important subtype in East Asia. Diabetes Metab Res Rev. 2011;27:959–64.PubMed Imagawa A, Hanafusa T. Fulminant type 1 diabetes–an important subtype in East Asia. Diabetes Metab Res Rev. 2011;27:959–64.PubMed
22.
go back to reference Kawabata Y, Nishida N, Awata T, Kawasaki E, Imagawa A, Shimada A, Osawa H, Tanaka S, Takahashi K, Nagata M, Yasuda H, Uchigata Y, Kajio H, Makino H, Yasuda K, Kobayashi T, Hanafusa T, Tokunaga K, Ikegami H. Genome-wide association study confirming a strong effect of HLA and identifying variants in CSAD/lnc-ITGB7–1 on chromosome 12q13.13 associated with susceptibility to fulminant type 1 diabetes. Diabetes. 2019;68:665–75.PubMed Kawabata Y, Nishida N, Awata T, Kawasaki E, Imagawa A, Shimada A, Osawa H, Tanaka S, Takahashi K, Nagata M, Yasuda H, Uchigata Y, Kajio H, Makino H, Yasuda K, Kobayashi T, Hanafusa T, Tokunaga K, Ikegami H. Genome-wide association study confirming a strong effect of HLA and identifying variants in CSAD/lnc-ITGB7–1 on chromosome 12q13.13 associated with susceptibility to fulminant type 1 diabetes. Diabetes. 2019;68:665–75.PubMed
23.
go back to reference Evangelou M, Smyth DJ, Fortune MD, Burren OS, Walker NM, Guo H, Onengut-Gumuscu S, Chen W-M, Concannon P, Rich SR, Todd JA, Wallace C. A method for gene-based pathway analysis using genome wide association study summary statistics reveals nine new type 1 diabetes associations. Genet Epidemiol. 2014;38:661–70.PubMedPubMedCentral Evangelou M, Smyth DJ, Fortune MD, Burren OS, Walker NM, Guo H, Onengut-Gumuscu S, Chen W-M, Concannon P, Rich SR, Todd JA, Wallace C. A method for gene-based pathway analysis using genome wide association study summary statistics reveals nine new type 1 diabetes associations. Genet Epidemiol. 2014;38:661–70.PubMedPubMedCentral
24.
go back to reference Sirdah MM. Protective and therapeutic effectiveness of taurine in diabetes mellitus: a rationale for antioxidant supplementation. Diabetes Metab Syndr. 2015;9:55–64.PubMed Sirdah MM. Protective and therapeutic effectiveness of taurine in diabetes mellitus: a rationale for antioxidant supplementation. Diabetes Metab Syndr. 2015;9:55–64.PubMed
25.
go back to reference Lambert IH, Kristensen DM, Holm JB, Mortensen OH. Physiological role of taurine–from organism to organelle. Acta Physiol (Oxf). 2015;213:191–21212. Lambert IH, Kristensen DM, Holm JB, Mortensen OH. Physiological role of taurine–from organism to organelle. Acta Physiol (Oxf). 2015;213:191–21212.
26.
go back to reference Huxtable RJ. Physiological actions of taurine. Physiol Rev. 1992;72:101–63.PubMed Huxtable RJ. Physiological actions of taurine. Physiol Rev. 1992;72:101–63.PubMed
27.
go back to reference Marcinkiewicz J, Kontny E. Taurine and inflammatory diseases. Amino Acids. 2014;46:7–20.PubMed Marcinkiewicz J, Kontny E. Taurine and inflammatory diseases. Amino Acids. 2014;46:7–20.PubMed
28.
go back to reference Kim C, Cha Y-N. Taurine chloramine produced from taurine under inflammation provides anti-inflammatory and cytoprotective effects. Amino Acids. 2014;46:89–100.PubMed Kim C, Cha Y-N. Taurine chloramine produced from taurine under inflammation provides anti-inflammatory and cytoprotective effects. Amino Acids. 2014;46:89–100.PubMed
29.
go back to reference Fakruddin M, Wei F, Suzuki T, et al. Defective mitochondrial tRNA taurine modification activates global proteostress and leads to mitochondrial disease. Cell Rep. 2018;22:482–96.PubMed Fakruddin M, Wei F, Suzuki T, et al. Defective mitochondrial tRNA taurine modification activates global proteostress and leads to mitochondrial disease. Cell Rep. 2018;22:482–96.PubMed
30.
go back to reference Ohsawa Y, Hagiwara H, Nishimatsu S, et al. Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicenter, open-label, 52-week phase III trial. J Neurol Neurosurg Psychiatry. 2019;90:529–36.PubMed Ohsawa Y, Hagiwara H, Nishimatsu S, et al. Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicenter, open-label, 52-week phase III trial. J Neurol Neurosurg Psychiatry. 2019;90:529–36.PubMed
31.
go back to reference Arany E, Strutt B, Romanus P, Remacle C, Reusens B, Hill DJ. Taurine supplement in early life altered islet morphology, decreased insulitis and delayed the onset of diabetes in non-obese diabetic mice. Diabetologia. 2004;47:1831–7.PubMed Arany E, Strutt B, Romanus P, Remacle C, Reusens B, Hill DJ. Taurine supplement in early life altered islet morphology, decreased insulitis and delayed the onset of diabetes in non-obese diabetic mice. Diabetologia. 2004;47:1831–7.PubMed
32.
go back to reference Lin S, Yang J, Wu G, Liu M, Lv Q, Yang Q, Hu J. Inhibitory effects of taurine on STZ-induced apoptosis of pancreatic islet cells. Adv Exp Med Biol. 2013;775:287–97.PubMed Lin S, Yang J, Wu G, Liu M, Lv Q, Yang Q, Hu J. Inhibitory effects of taurine on STZ-induced apoptosis of pancreatic islet cells. Adv Exp Med Biol. 2013;775:287–97.PubMed
33.
go back to reference Volders PJ, Verheggen K, Menschaert G, Vandepoele K, Martens L, Vandesompele J, Mestdagh P. An update on LNCipedia: a database for annotated human lncRNA sequences. Nucleic Acids Res. 2015;43:D174–D180180.PubMed Volders PJ, Verheggen K, Menschaert G, Vandepoele K, Martens L, Vandesompele J, Mestdagh P. An update on LNCipedia: a database for annotated human lncRNA sequences. Nucleic Acids Res. 2015;43:D174–D180180.PubMed
34.
go back to reference Westra HJ, Peters MJ, Esko T, et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat Genet. 2013;45:1238–43.PubMedPubMedCentral Westra HJ, Peters MJ, Esko T, et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat Genet. 2013;45:1238–43.PubMedPubMedCentral
35.
go back to reference Narahara M, Higasa K, Nakamura S, Tabara Y, Kawaguchi T, Ishii M, Matsubara K, Matsuda F, Yamada R. Large-scale East-Asian eQTL mapping reveals novel candidate genes for LD mapping and the genomic landscape of transcriptional effects of sequence variants. PLoS ONE. 2014;9:e100924.PubMedPubMedCentral Narahara M, Higasa K, Nakamura S, Tabara Y, Kawaguchi T, Ishii M, Matsubara K, Matsuda F, Yamada R. Large-scale East-Asian eQTL mapping reveals novel candidate genes for LD mapping and the genomic landscape of transcriptional effects of sequence variants. PLoS ONE. 2014;9:e100924.PubMedPubMedCentral
36.
go back to reference Higasa K, Miyake N, Yoshimura J, et al. Human genetic variation database, a reference database of genetic variations in the Japanese population. J Hum Genet. 2016;61:547–53.PubMedPubMedCentral Higasa K, Miyake N, Yoshimura J, et al. Human genetic variation database, a reference database of genetic variations in the Japanese population. J Hum Genet. 2016;61:547–53.PubMedPubMedCentral
37.
go back to reference Berlin C, Berg EL, Briskin MJ, Andrew DP, Kilshaw PJ, Holzmann B, Weissman IL, Hamann A, Butcher EC. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell. 1993;74:185–95.PubMed Berlin C, Berg EL, Briskin MJ, Andrew DP, Kilshaw PJ, Holzmann B, Weissman IL, Hamann A, Butcher EC. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell. 1993;74:185–95.PubMed
38.
go back to reference Streeter PR, Berg EL, Rouse BT, Bargatze RF, Butcher EC. A tissue-specific endothelial cell molecule involved in lymphocyte homing. Nature. 1988;331:41–6.PubMed Streeter PR, Berg EL, Rouse BT, Bargatze RF, Butcher EC. A tissue-specific endothelial cell molecule involved in lymphocyte homing. Nature. 1988;331:41–6.PubMed
39.
go back to reference Hänninen A, Taylor C, Streeter PR, Stark LS, Sarte JM, Shizuru JA, Simell O, Michie SA. Vascular addressins are induced on islet vessels during insulitis in nonobese diabetic mice and are involved in lymphoid cell binding to islet endothelium. J Clin Invest. 1993;92:2509–15.PubMedPubMedCentral Hänninen A, Taylor C, Streeter PR, Stark LS, Sarte JM, Shizuru JA, Simell O, Michie SA. Vascular addressins are induced on islet vessels during insulitis in nonobese diabetic mice and are involved in lymphoid cell binding to islet endothelium. J Clin Invest. 1993;92:2509–15.PubMedPubMedCentral
40.
go back to reference Faveeuw C, Gagnerault MC, Lepault F. Expression of homing and adhesion molecules in infiltrated islets of Langerhans and salivary glands of nonobese diabetic mice. J Immunol. 1994;152:5969–78.PubMed Faveeuw C, Gagnerault MC, Lepault F. Expression of homing and adhesion molecules in infiltrated islets of Langerhans and salivary glands of nonobese diabetic mice. J Immunol. 1994;152:5969–78.PubMed
41.
go back to reference Yang XD, Sytwu HK, McDevitt HO, Michie SA. Involvement of beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in the development of diabetes in obese diabetic mice. Diabetes. 1997;46:1542–7.PubMed Yang XD, Sytwu HK, McDevitt HO, Michie SA. Involvement of beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in the development of diabetes in obese diabetic mice. Diabetes. 1997;46:1542–7.PubMed
Metadata
Title
Genetics of fulminant type 1 diabetes
Authors
Yumiko Kawabata
Hiroshi Ikegami
Publication date
01-10-2020
Publisher
Springer Singapore
Keyword
Type 1 Diabetes
Published in
Diabetology International / Issue 4/2020
Print ISSN: 2190-1678
Electronic ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-020-00468-0

Other articles of this Issue 4/2020

Diabetology International 4/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.